FILTER

Refine your search with the following facets to narrow down your results.

4 Current news of Proximagen Neuroscience

Proximagen enters into a Collaboration Agreement with the NIH for a Phase II clinical trial on naluzotan

08-Jul-2010 - Proximagen Group plc announced that it has signed a Collaboration Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) in the United States. Under the terms of the CRADA, NINDS will fully ...

clinical trials epilepsy neurological disorders +2

Proximagen sublicenses rights to tonabersat in North America

14-Apr-2010 - Proximagen Neuroscience plc announced that it has signed a development, license and sub-license agreement with Upsher-Smith Laboratories Inc.in relation to tonabersat, a drug compound recently acquired by Proximagen through its acquisition of Minster Pharmaceuticals plc. Under the terms of the ...

epilepsy GSK license agreements +1

Proximagen announces positive efficacy results in NIH epilepsy studies

15-Mar-2010 - Proximagen Neuroscience plc announced headline results from the successful completion of a year-long non-clinical testing programme undertaken by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institute of Health (NIH) in the United States, which confirm ...

drug development epilepsy neurological disorders +4

Biovitrum Completes Divestiture of Cambridge Biotechnology

25-Nov-2009 - Biovitrum AB announced that it has completed the divestiture of its wholly-owned subsidiary Cambridge Biotechnology Ltd (CBT), and the sale of certain drug development programs, to Proximagen Neuroscience plc. The drug development programs consist of the pre-clinical stage programs VAP-1 and ...

Biovitrum drug development recombinant proteins